Education
About Us
Working with TipRanks
Follow Us
89Bio Inc (ETNB)
:ETNB
ETNB Stock Chart & Stats
$14.84
$0.27(4.28%)
At close: 4:00 PM EST
$14.84
$0.27(4.28%)
Day’s Range― - ―
52-Week Range― - ―
Previous Close$6.59
Volume1.55M
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$561.16M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition Premium89bio announced that it has entered into a merger agreement to be acquired by Roche at a price of $14.50 per share in cash at closing, representing a premium of approximately 79% to ETNB's closing stock price on September 17.
Market PotentialHigh conviction in the MASH space as a large and growing market with the FGF21 class being one of the most potent anti-fibrotic mechanisms in development.
Strategic FitThis transaction reflects pegozafermin's potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis and highlights its strategic fit within Roche's cardiovascular, renal, and metabolism portfolio.
Bears Say
89bio News
ETNB FAQ
What was 89Bio Inc’s price range in the past 12 months?
Currently, no data Available
What is 89Bio Inc’s market cap?
Currently, no data Available
When is 89Bio Inc’s upcoming earnings report date?
89Bio Inc’s upcoming earnings report date is Nov 06, 2025 which is 44 days ago.
How were 89Bio Inc’s earnings last quarter?
89Bio Inc released its earnings results on Aug 07, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.209.
Is 89Bio Inc overvalued?
According to Wall Street analysts 89Bio Inc’s price is currently Overvalued.
Does 89Bio Inc pay dividends?
89Bio Inc does not currently pay dividends.
What is 89Bio Inc’s EPS estimate?
89Bio Inc’s EPS estimate is -0.5.
How many shares outstanding does 89Bio Inc have?
Currently, no data Available
What happened to 89Bio Inc’s price movement after its last earnings report?
89Bio Inc reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 1.552%.
Which hedge fund is a major shareholder of 89Bio Inc?
Currently, no hedge funds are holding shares in ETNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
89Bio Inc
89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's core product candidate, pegozafermin, is designed to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Operating primarily within the biotechnology sector, 89bio aims to address the significant unmet medical needs associated with these conditions by advancing its novel therapeutic solutions through clinical trials.
Technical Analysis
Travere Therapeutics
―
Immunovant
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Dyne Therapeutics
―
Ownership Overview
Currently, No data available
---